We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.055 | -2.52% | 2.125 | 2.05 | 2.20 | 2.25 | 2.10 | 2.20 | 2,365,381 | 16:35:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.89 | 7.17M |
Date | Subject | Author | Discuss |
---|---|---|---|
15/12/2017 11:03 | Stephen2010. Your spam-tastic :) | hamhamham1 | |
15/12/2017 10:58 | As I posted yesterday evening. Check out ALBA. Huge multibag potential. ALBA currently trading at 0.39p target price 6p making a nice 15 bagger. Please read the following: MARKET CAP PUZZLE ❖ Alba (market cap £8.4m) is in a resources neighbourhood populated with listed companies with much enhanced market capitalisations, such as UKOG.L (£134m) and JAY.L (£172m). With either shared project interests or adjacent tenements to these companies, Alba should trade at a much higher valuation than its current token value. Like Bluejay, Alba owns 100% of its ilmenite project. Direct comparisons with UKOG are also instructive. While both companies own other projects, UKOG’s 49.9% of Horse Hill Developments Limited (HHDL), when compared to Alba’s 18.1% means that Alba has approximately one third of the value of Horse Hill compared to UKOG but only about 7% of the market capitalisation. Once the market recognises these disparities, the room for growth in Alba’s share price is undeniable. VALUATION RATIONALE - Our valuation in this First Equity Limited initiation note uses a risked valuation approach for Alba’s two main projects, at Horse Hill and TBS. The Horse Hill licences are valued using independent published technical data from Schlumberger, Xodus and Nutech on the oil potential of the licences, along with our own assumptions on recovery rates, oil discovery value, resource and development risks factors. From this a risked value of $127m net to Alba on a ‘Base Case’ basis is derived for Horse Hill. Given the similar geology and economic potential of both TBS and Dundas, we have adopted a risked closeology valuation approach, by computing an NPV for Dundas of $223m and then applying a three-tiered risked probability calculation to arrive at a value of $54.7m for TBS. Once Alba announce its JORC resource and exploration target at TBS and Bluejay its Feasibility Study results, this number is likely to be revised upwards very rapidly, possibly up to $200m, representing up to 7p per share in additional shareholder value. We compute a valuation of $185m (£139m) for Alba, equating to 6.0p per share, of which 4.1p is attributed to the stake in Horse Hill, 1.8p for TBS. Given this analysis and wealth of valuation catalysts anticipated across the project portfolio in the coming months, we recommend the shares as a ‘BUY, with a Target Price of 6.0p, representing a potential 15 times plus uplift from the current share price. | stephen2010 | |
15/12/2017 09:45 | MM’s ready to mug anymore festive sellers, most have probably worked out not to sell one bring this close to potentially huge game changing news for IMM If majority of buyers are holding, the stock shortage will become more apparent and the share price will keep rising. It’s following a similar pattern after previous leg ups. | ny boy | |
15/12/2017 09:31 | premuims being paid for anything 5k up | sportbilly1976 | |
15/12/2017 08:10 | It works alright. | top tips | |
15/12/2017 08:03 | 8p spread Lol | herschel k | |
15/12/2017 08:00 | "I am only putting enough on here that, if lost, wouldn't be any trouble"" Sensible approach with any company's shares these days!! | gbh2 | |
14/12/2017 21:58 | A good investment advice i.e. "... as much as I like the share, I am still keeping it in perspective (financially). I am only putting enough on here that, if lost, wouldn't be any trouble" | ashehzi | |
14/12/2017 21:47 | Thanks mate | jp1962 | |
14/12/2017 21:39 | Probably more like end of January I reckoned but it’s all a guess really, only IMM will know, maybe the share price will give us clues also, always leaky leaky on a major event. Not long to wait only 27 trading days to go now! | ny boy | |
14/12/2017 20:56 | Are the results likely to come out in jan | jp1962 | |
14/12/2017 20:49 | But as much as I like the share, I am still keeping it in perspective (financially). I am only putting enough on here that, if lost, wouldn't be any trouble. | hamhamham1 | |
14/12/2017 20:01 | Yep I totally agree. Without the knowledge of P3 results and any subsequent FDA approval then this is a different kettle of fish. So there are lots of reasons at this point for IMM to be valued substantially less. Lets face it, its a gamble, but I'm basing my gamble on the results to date, Benlysta's path cutting (first new Lupus drug in 50 years) and the P140 innovative platform (blocking transmission above the T cell rather than blasting the low level B cells). That is if I understand the approach :) | hamhamham1 | |
14/12/2017 19:55 | Will gsk buy this | stevenrevell | |
14/12/2017 19:50 | Yes, hamhamham, but what was the market capital of HGS the day before its P3 read out, and then on FDA approval, and then on the GSK buyout? | divmad | |
14/12/2017 19:10 | When Human Genome Sciences, HGS (who jointly developed Benlysta with GSK) was bought out by GSK (both companies having a 50% stake each in Benlysta). HGS market capital was valued at about $1.8bn the day before the buyout offer, then the offer (offer equiv to $3.6bn) this was at a 99% premium to the previous days closing price. So a regular days market price is one thing, then the next day if someone wants to buy you out well then that's another thing altogether. | hamhamham1 | |
14/12/2017 19:09 | IMM Immupharma....... a look at the' feet on the ground' hxxp://www.epo.org/l | 3rd eye | |
14/12/2017 18:58 | The target given by a recent broker is £9 if successful so £16 seems a tad rich! | jp1962 | |
14/12/2017 18:53 | Anyone who can afford to never work again if a share is a 10 bagger must have a pretty large stake in that company imo | spawny100 | |
14/12/2017 18:49 | Come on 10 bagger! You sure lol.I wish as I would never have to work again if that was the case! | jp1962 | |
14/12/2017 18:45 | Positive results = 10 bagger it's as simple as that.. I keep looking for other stocks maybe to top slice my overweight position here. can't find anything like it. | blackbear | |
14/12/2017 17:09 | Exactly spawny. If news is good no chance im selling anything before any deal is announced | immy1992 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions